Riverpark Capital Management LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 15.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 46,091 shares of the life sciences company’s stock after selling 8,133 shares during the period. Riverpark Capital Management LLC’s holdings in Illumina were worth $10,071,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Nationwide Fund Advisors increased its position in shares of Illumina by 0.8% during the 3rd quarter. Nationwide Fund Advisors now owns 102,393 shares of the life sciences company’s stock valued at $20,397,000 after purchasing an additional 848 shares during the last quarter. Canada Pension Plan Investment Board increased its position in shares of Illumina by 110.1% during the 3rd quarter. Canada Pension Plan Investment Board now owns 19,210 shares of the life sciences company’s stock valued at $3,827,000 after purchasing an additional 10,068 shares during the last quarter. Andra AP fonden increased its holdings in Illumina by 12.3% in the 3rd quarter. Andra AP fonden now owns 7,300 shares of the life sciences company’s stock worth $1,454,000 after acquiring an additional 800 shares in the last quarter. Dupont Capital Management Corp purchased a new stake in Illumina in the 3rd quarter worth approximately $153,000. Finally, Prudential Financial Inc. increased its holdings in Illumina by 0.3% in the 3rd quarter. Prudential Financial Inc. now owns 201,160 shares of the life sciences company’s stock worth $40,071,000 after acquiring an additional 540 shares in the last quarter. Institutional investors and hedge funds own 91.51% of the company’s stock.
Illumina, Inc. (NASDAQ:ILMN) opened at $250.12 on Monday. The company has a current ratio of 3.99, a quick ratio of 3.55 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $36,767.64, a P/E ratio of 62.37, a PEG ratio of 3.31 and a beta of 0.93. Illumina, Inc. has a 52-week low of $158.02 and a 52-week high of $250.67.
In related news, Director A Blaine Bowman sold 3,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $230.82, for a total value of $692,460.00. Following the completion of the sale, the director now directly owns 19,868 shares in the company, valued at $4,585,931.76. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Frances Arnold sold 250 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $241.50, for a total value of $60,375.00. Following the completion of the sale, the director now owns 10,439 shares of the company’s stock, valued at $2,521,018.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,887 shares of company stock valued at $16,510,025. 0.89% of the stock is owned by corporate insiders.
Several equities research analysts recently issued reports on the stock. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Saturday. Evercore ISI assumed coverage on shares of Illumina in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $250.00 target price for the company. Canaccord Genuity reissued a “buy” rating and issued a $265.00 target price (up from $255.00) on shares of Illumina in a report on Wednesday, January 31st. Leerink Swann increased their target price on shares of Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, Barclays increased their price objective on shares of Illumina from $200.00 to $215.00 and gave the company an “equal weight” rating in a report on Wednesday, January 31st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $241.39.
ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/12/illumina-inc-ilmn-shares-sold-by-riverpark-capital-management-llc.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.